Payment overview · 2025
General Payments
$30.47
2 reported records · 2 companies
Healthcare provider profile · identity verified
Martha Lee O'Reilly, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLIFTON, TX · NPI 1285788521
Verified facts
What the public records show
CMS Open Payments records show Martha Lee O'Reilly, MD received $30.47 in general payments during 2025 across 2 reported records.
Exact Sciences Corporation accounted for 55.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.78 | 55.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.69 | 44.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $30.47 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 403 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 79 |
| Gabapentin | Gabapentin | 258 | 56 |
| Montelukast Sodium | Montelukast Sodium | 256 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 61 |
| Losartan Potassium | Losartan Potassium | 193 | 54 |
| Lisinopril | Lisinopril | 165 | 35 |
| Simvastatin | Simvastatin | 147 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 139 | 33 |
| Famotidine | Famotidine | 129 | 23 |
| Metformin Hcl | Metformin Hcl | 128 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 25 |
| Sertraline Hcl | Sertraline Hcl | 115 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 24 |
| Carvedilol | Carvedilol | 105 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 16 |
| Tramadol Hcl | Tramadol Hcl | 84 | 24 |
| Ezetimibe | Ezetimibe | 80 | 24 |
| Omeprazole | Omeprazole | 80 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 18 |
| Alendronate Sodium | Alendronate Sodium | 75 | 12 |
| Potassium Chloride | Potassium Chloride | 75 | 18 |
| Eliquis | Apixaban | 73 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 17 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 13 |
| Buspirone Hcl | Buspirone Hcl | 63 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 62 | 17 |
| Furosemide | Furosemide | 62 | 19 |
| Metformin Hcl Er | Metformin Hcl | 61 | 16 |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Jardiance | Empagliflozin | 59 | 11 |
| Ozempic | Semaglutide | 59 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 59 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Alprazolam | Alprazolam | 53 | 12 |
| Spironolactone | Spironolactone | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 12 |
| Allopurinol | Allopurinol | 51 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Atenolol | Atenolol | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 41 | suppressed |
| Premarin | Estrogens, Conjugated | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Acarbose | Acarbose | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | 12 |
| Baclofen | Baclofen | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fluconazole | Fluconazole | 13 | 12 |
| Meloxicam | Meloxicam | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30.47 · 2 records | Exact Sciences Corporation | ELIQUIS, NURTEC ODT, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error